Oncology and Hematology - Global Oncology Academy

Episodes 33-48 of 107

First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy
First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy
MinuteCE®
First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy
1.25 program credits
- Aparna R. Parikh, MD
1.25 program credits
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
MinuteCE®
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
1.25 program credits
- Alan Venook, MD
1.25 program credits
Emerging Treatment Approaches for EBC
Emerging Treatment Approaches for EBC
MinuteCE®
Emerging Treatment Approaches for EBC
1.50 program credits
- William J. Gradishar, MD
1.50 program credits
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
MinuteCE®
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
MinuteCE®
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
MinuteCE®
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
MinuteCE®
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
1.50 program credits
- Erica L. Mayer, MD, MPH
1.50 program credits
Testosterone Revisited: Importance of Monitoring and Impact of Rebound on Quality of Life in Advanced Prostate Cancer
Testosterone Revisited: Importance of Monitoring and Impact of Rebound on Quality of Life in Advanced Prostate Cancer
MinuteCE®
Testosterone Revisited: Importance of Monitoring and Impact of Rebound on Quality of Life in Advanced Prostate Cancer
0.75 program credits
- Tanya Dorff, MD
0.75 program credits
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
MinuteCE®
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
1.00 program credit
- Ritu Salani, MD, MBA
- Nicoletta Colombo, MD
1.00 program credit
Emerging targeted therapy combination strategies in genitourinary malignancies
Emerging targeted therapy combination strategies in genitourinary malignancies
MinuteCE®
Emerging targeted therapy combination strategies in genitourinary malignancies
1.25 program credits
- Ignacio Duran, MD
1.25 program credits
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
MinuteCE®
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
1.25 program credits
- Ignacio Duran, MD
- Wenxin Xu, MD
1.25 program credits
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
MinuteCE®
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
0.75 program credits
- Rana McKay, MD
0.75 program credits
Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer
Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer
MinuteCE®
Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer
1.00 program credit
- Ritu Salani, MD, MBA
- Susana Campos, MD, MPH
1.00 program credit
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
MinuteCE®
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
1.25 program credits
- Ignacio Duran, MD
- Wenxin Xu, MD
1.25 program credits
MinuteCE®
Advancing Prostate Cancer Care: Integrating Guideline Updates and Patient Preferences for Optimal ADT Management of Advanced Prostate Cancer
0.75 credits 7 episodes
- Tanya Dorff, MD
- Rana McKay, MD
0.75 credits 7 episodes
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
MinuteCE®
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
1.25 program credits
- Ignacio Duran, MD
- Wenxin Xu, MD
1.25 program credits

3/7